FDA arranges Feb. 26 AdComm to discuss J&J COVID-19 vaccine EUA City of Chicago turns to Zocdoc to help get COVID-19 vaccines into arms Gilead sees a blockbuster 2021 for COVID-19 drug Veklury but can grow without it: CFO U.K. government taps CureVac to target COVID-19 variants with new vaccines UPDATED Coronavirus tracker: Feds to prioritize Pfizer vaccine equipment; invest in glove production 'How safe does this make my family member?' What doctors should tell patients about COVID-19 vaccine No need 'to start at square one': FDA plans to lay out a speedy path for COVID vaccines, drugs against variants All eyes on Regeneron's COVID-19 antibodies, but Dupixent's still driving the bus OIG: Part D opioid prescriptions dipped during onset of COVID-19 pandemic Moderna sets sights on $200M vaccine factory in Seoul: report Pitt team sheds light on how COVID-19 escapes immune destruction Featured Story | By Nick Paul Taylor Johnson & Johnson has filed for emergency FDA authorization of its one-dose COVID-19 vaccine. The FDA has scheduled an advisory committee meeting to discuss the application for Feb. 26. read more |
| |
|---|
|
| | Webinar: The Benefits of Pharmacist-Led Clinical Trials Tuesday, February 23, 2021 | 1pm ET / 10am PT This webinar will focus on how a pharmacist-led clinical trial model impacts the six key areas most relevant to clinical trials in today’s COVID and Decentralized Clinical Trial environment: regulations, recruiting, diversity, clinical outcomes, data integrity, and clinical supply chain. Register Now. |
Top Stories By Heather Landi Cities have been turning to technology companies to help with one of the most difficult logistics challenges in history: equitably and efficiently distributing the COVID-19 vaccine. Chicago is teaming up with Zocdoc, and some cities are working with a cybersecurity firm to ensure equitable vaccine distribution. read more By Eric Sagonowsky Early in the COVID-19 pandemic, as researchers scrambled to find medicines that could treat the new and mysterious disease, Gilead Sciences' remdesivir quickly marched to worldwide prominence based on promising early data. Now, with a full FDA approval in hand, Veklury is pulling in big sales—and has a big 2021 ahead, execs said. read more By Amirah Al Idrus On the heels of COVID-19 pacts with Bayer and GlaxoSmithKline, CureVac is joining forces with the U.K. government to tackle the next challenge—new variants of the SARS-CoV-2 virus. If approved, any vaccines that come out of the deal will be distributed in the U.K. and its overseas and dependent territories. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Tina Reed As more patients get vaccinated against COVID-19, here's what experts say doctors should tell patients about what they can—and still should not—do. read more By Angus Liu New coronavirus variants have prompted COVID-19 vaccine makers to start developing updates to their existing offerings. To speed their journey to a pandemic-fatigued public, the FDA says it’s developing expedited review rules for the follow-up shots. read more By Beth Snyder Bulik Regeneron's bullish outlook for its COVID-19 antibody therapy continues to outpace its sales figures, but strong Dupixent and Eylea revenues in the third quarter took some of the pressure off. Dupixent notched $1.17 billion, a 56% increase year over year, while Eylea grew 10% to reach $1.34 billion. Total growth? 30%. read more By Robert King A new report from a Department of Health and Human Services watchdog found roughly 1 in 5 Part D beneficiaries got an opioid in the first eight months of 2020. read more By Fraiser Kansteiner Moderna, which will supply at least 40 million doses of its vaccine to South Korea, may be looking to set up shop in the country, a former government minister involved in talks with the drugmaker said. It's allegedly hatching plans with the government to prop up a $200-million vaccine plant in Seoul, multiple sources report. read more By Arlene Weintraub University of Pittsburgh researchers discovered that SARS-CoV-2 deletes part of its genetic code, allowing it to evade the immune response. The insights could help drug and vaccine developers tweak their COVID-19 remedies over time to stay ahead of the virus. read more |
